; or (B) trade secrets with respect to any entities. . 14. GAO study on price-related compensation across the supply chain Section 1860D–42 of the Social Security Act ( 42 U.S.C. 1395w–152 ), as amended by section 13, is amended by adding at the end the following new subsection: (h) GAO study and report on price-related compensation and payment structures in the prescription drug supply chain (1) Study The Comptroller General of the United States (in this subsection referred to as the Comptroller General ) shall conduct a study describing the use of compensation and payment structures related to a prescription drug’s price within the retail prescription drug supply chain in this part. Such study shall summarize information from Federal agencies and industry experts, to the extent available, with respect to the following: (A) The type, magnitude, other features (such as the pricing benchmarks used), and prevalence of compensation and payment structures related to a prescription drug’s price, such as calculating fee amounts as a percentage of a prescription drug’s price, between intermediaries in the prescription drug supply chain, including— (i) pharmacy benefit managers; (ii) part D plan sponsors; (iii) drug wholesalers; (iv) pharmacies; (v) manufacturers; (vi) pharmacy services administrative organizations; (vii) brokers, auditors, consultants, and other entities that advise part D plan sponsors about pharmacy benefits or review part D plan sponsor contracts with pharmacy benefit managers